Bioinvent: No drama in Q1 – key milestones approaching

Research Note

2019-05-22

17:18

Today’s Q1 2019 earnings report was mostly uneventful. All the 2019 catalyst remain on track, and the closest is a first look of the data from the ongoing combination study with BI-1206, expected in mid-June. Following the report, we reiterate our base case fair value of SEK 4.

KP

Klas Palin

Sign up for free to continue

Already a member?

Sign in

Disclosures and disclaimers

Premium Plan required to unlock

Unlock companies to access

more high quality research.